The aggregation of alpha synuclein (α‐syn) is a neuropathological feature that defines a
spectrum of disorders collectively termed synucleinopathies, and of these, Parkinson's …

The development of novel therapies against neurodegenerative disorders requires the
ability to detect their early, presymptomatic manifestations in order to enable treatment …

ABSTRACT α-Synuclein (α-Syn) aggregation in Lewy bodies and Lewy neurites has
emerged as a key pathogenetic feature in Parkinson's disease, dementia with Lewy bodies …

Progressive accumulation of α-synuclein (α-syn) in limbic and striatonigral systems is
associated with the neurodegenerative processes in dementia with Lewy bodies (DLB) and …

Abstract Development of neuroprotective therapeutics for Parkinson's disease (PD) is facing
a lack of translation from pre-clinical to clinical trials. One strategy for improvement is to …

While studying transgenic mice that overexpress human wildtype alpha-synuclein (Thy1-
ASO, ASO) for typical brain alpha-synucleinopathy and central nervous system …

Abstract Parkinson disease (PD; MIM 168600) is the second most common progressive
neurodegenerative disorder characterized by a variety of motor and non-motor features. To …

Exosomes play a key role in delivery of various biological material and complex signals from
one cell to another at long distances. These small extracellular vehicles are involved in …

Synucleinopathies are a group of neurodegenerative diseases that share a common
pathological lesion of intracellular protein inclusions largely composed by aggregates of …

Understanding regulation of α-synuclein has long been a central focus for Parkinson's
disease (PD) researchers. Accumulation of this protein in the Lewy body or neurites …